LifeMD
Virtual healthcare platform
Fast-growing telehealth company with partnerships with both Eli Lilly and Novo Nordisk for affordable brand-name GLP-1 access.
Medications Available
Pros
- Partnerships with both Lilly and Novo Nordisk
- FDA-approved medications
- First major telehealth provider to add Foundayo (orforglipron) — April 10, 2026
- Wegovy HD 7.2mg available since April 2026
- Affordable manufacturer pricing
- Full-service weight loss programs
- Large established patient base
Cons
- No compounded options
- Cash-pay only
- Limited to brand-name medications
Compare LifeMD With
See how LifeMD stacks up against other providers
How LifeMD Ranks
See where LifeMD places in our expert rankings
About LifeMD
LifeMD is a fast-growing telehealth company founded in 2018 in New York, NY, with over 275,000 active patients and 1.1 million virtual visits. They uniquely partner with both Eli Lilly (for Zepbound) and Novo Nordisk (for Wegovy) to offer affordable brand-name GLP-1 access.
How It Works
- Online Assessment - Complete health questionnaire
- Video Consultation - Meet with LifeMD providers
- Choose Medication - Zepbound or Wegovy
- Manufacturer Pricing - Access discounted rates through partnerships
Pricing (May 2026)
| Medication | Price | Notes |
|---|---|---|
| Program Fee | $75-119/mo | LifeMD Weight Management membership |
| Foundayo (orforglipron) 0.8mg starter | $149/mo | NEW oral pill, no food/water restrictions, via LillyDirect |
| Foundayo 2.5mg | $199/mo | Step-up dose |
| Foundayo 5.5mg-17.2mg | $299/mo | Maintenance doses |
| Wegovy Pill (1.5mg, 4mg) | $199/mo | Intro $149 ended April 15, 2026 |
| Wegovy Pill (9mg, 25mg) | $299/mo | Maintenance oral doses |
| Wegovy HD 7.2mg Injection | $399/mo | NEW high-dose semaglutide (launched April 7, 2026) |
| Wegovy Injection Intro | $199/mo | First 2 fills (0.25-0.5mg), extended through June 30, 2026 |
| Wegovy Injection Standard | $349-499/mo | Via NovoCare Pharmacy |
| Zepbound 2.5mg | $299/mo | Via LillyDirect |
| Zepbound 5mg | $399/mo | Via LillyDirect |
| Zepbound 7.5mg-15mg (multi-dose pen) | $449/mo | Via LillyDirect |
10% weight loss guarantee after 1 year or refund. Direct partnerships with both major GLP-1 manufacturers. Approximately 75,000 active weight management subscribers. Medicare beneficiaries pay no more than $50/mo for Zepbound multi-dose pen — coverage went live April 1, 2026. Foundayo Medicare coverage at $50/mo expected to begin July 1, 2026.
Who Is This Best For?
- Patients wanting FDA-approved medications only
- Those seeking manufacturer-discounted pricing
- People who want access to both Zepbound and Wegovy
- Patients preferring established telehealth providers
The Bottom Line
LifeMD’s dual partnerships with both Eli Lilly and Novo Nordisk make it the most comprehensive brand-name GLP-1 telehealth platform on the market. With the addition of Foundayo (the new no-restriction oral pill from Lilly) and Wegovy HD 7.2mg in April 2026, LifeMD now offers the broadest FDA-approved GLP-1 lineup of any telehealth provider — branded oral and injectable options from both manufacturers.
Last updated: May 2026
Last verified: May 2026
Ready to try LifeMD?
Compare with other providers or visit their website to get started.